论文部分内容阅读
目的:探讨经典霍奇金淋巴瘤(cHL)患者在自体干细胞移植(ASCT)前或后行n 18F-脱氧葡萄糖(FDG)PET/CT显像及相关因素的预测预后价值。n 方法:回顾性收集2008年1月至2017年6月间在上海交通大学附属第一人民医院经病理检查证实的55例cHL患者[男28例，女27例，年龄(28.8±9.6)岁]，其中43例在ASCT前、34例在ASCT后行n 18F-FDG PET/CT显像(22例在移植前后均行显像)。依据Deauville五分法分别将ASCT前或后PET/CT显像结果分为阳性(≥4分)和阴性组(<4分)。采用Kaplan-Meier法绘制生存曲线，分析无进展生存(PFS)和总生存(OS)，并通过log-rank检验比较组间差异；通过Cox回归模型计算生存影响因素的风险比(n HR)。n 结果:55例cHL患者中，29例(53%)中位随访8个月后病情进展，11例(20%)在中位随访29.5个月后死亡；3年PFS率为46.4%，OS率为84.5%。有无B症状组间，有无纵隔大肿块组间，国际预后评分(IPS)低危组(0～2分)与高危组(3～7分)组间，挽救性化疗完全缓解(CR)、部分缓解(PR)或疾病稳定(SD)、疾病进展(PD)组间，ASCT前显像阴性与阳性组间，ASCT后显像阴性与阳性组间PFS率差异均有统计学意义[n χ2值：5.52～20.01, n HR：2.21(95% n CI：1.56～3.12)～5.51(95% n CI：1.86～16.33)，均n P<0.05]。有无B临床症状和有无纵隔大肿块对预测OS有统计学意义[n HR＝5.28(95% n CI：1.14～24.51)和4.27(95% n CI：1.24～14.79)，均n P<0.05]。ASCT前、后n 18F-FDG PET/CT显像结果联合对预测PFS具有统计学意义(n χ2＝11.28，n P<0.01)。多因素分析显示ASCT后n 18F-FDG PET/CT显像阳性患者的进展风险明显高于显像阴性患者(n HR＝6.20，n P<0.01)；有B症状患者死亡的风险明显高于无B临床症状患者(n HR＝5.28，n P<0.05)。n 结论:ASCT后n 18F-FDG PET/CT显像结果能有效预测cHL患者ASCT后的PFS，有无B症状是预测ASCT后OS的重要指标。n “,”Objective:To assess the predictive value of n 18F-fluorodeoxyglucose (FDG) PET/CT imaging and relevant factors in the prognosis of patients with classic Hodgkin lymphoma (cHL) before or after autologous stem cell transplantation (ASCT).n Methods:From January 2008 to June 2017, 55 cHL patients (28 males, 27 females; age: (28.8±9.6) years) confirmed by pathology in Shanghai General Hospital were retrospectively included. n 18F-FDG PET/CT imaging was performed before ASCT in 43 cases and after ASCT in 34 cases (22 patients underwent the imaging both before and after ASCT). Patients were divided into positive group (≥4) and negative group (<4) according ton 18F-FDG PET/CT imaging results using Deauville 5-point scale. The predictive value of relevant factors in the prognosis was evaluated with progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis and log-rank test. Hazard ratio (n HR) was calculated by Cox regression model.n Results:Of 55 cHL patients, 29 (53%) had a progression of disease after a median follow-up of 8 months, and 11 (20%) patients died after a median follow-up of 29.5 months, with the 3-year PFS rate of 46.4% and OS rate of 84.5%. Significant differences of PFS rate were found between patients with or without B symptoms, between patients with or without large mediastinal mass, between patients with international prognostic score (IPS) of 0-2 and those with IPS of 3-7, among patients with different effect of salvage chemotherapy (complete remission (CR), partial remission (PR) + stable disease (SD), progressive disease (PD)), and between patients with negative or positive PET/CT imaging results before or after ASCT (n χ2 values: 5.52-20.01, n HR: 2.21(95% n CI: 1.56-3.12)-5.51(95% n CI: 1.86-16.33), all n P<0.05). B symptoms and large mediastinal mass were also prognostic factors for OS rate (n HR: 5.28(95% n CI: 1.14-24.51) and 4.27(95% n CI: 1.24-14.79), both n P<0.05). The combination ofn 18F-FDG PET/CT imaging before and after ASCT was statistically significant for predicting PFS (n χ2=11.28, n P<0.01). Multivariate survival analysis showed that the risk of progression in patients with positive PET/CT results after ASCT was significantly higher than those with negative results (n HR=6.20, n P<0.01), and the risk of death in patients with B symptoms was significantly higher than those without B symptoms (n HR=5.28, n P<0.05).n Conclusion:18F-FDG PET/CT imaging results after ASCT have important values for predicting PFS in cHL patients after ASCT, and B symptoms can be used as an important prognostic indicator of OS after ASCT.n